Xvivo Perfusion AB’s DeLIVER Trial: A Promising Step in Liver Transplantation

Xvivo Perfusion AB ((XVIPF)) announced an update on their ongoing clinical study.

Study Overview: The DeLIVER Trial, officially titled A Prospective, Multi-Center, Single-Arm, Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion, aims to confirm the safety and effectiveness of dual hypothermic oxygenated perfusion (DHOPE) using the Liver Assist device to preserve deceased donor livers for transplantation. This study is significant as it seeks to improve outcomes in liver transplant surgeries, potentially reducing organ discard rates.

Intervention/Treatment: The intervention being tested is the dual hypothermic oxygenated perfusion (DHOPE) device. This device is intended to restore hepatic ATP, reduce reperfusion injury, and improve outcomes in liver transplantation by preserving donor livers for up to 20 hours, thereby potentially increasing the usability of donor organs.

Study Design: This is an interventional study with a single-group assignment model. There is no masking involved, and the primary purpose is treatment. The study will involve participants requiring liver transplants, using donor organs subjected to DHOPE.

Study Timeline: The study is not yet recruiting, with the initial submission date on March 21, 2025, and the last update on March 31, 2025. These dates are crucial as they mark the beginning of the study’s lifecycle and its readiness to commence participant recruitment.

Market Implications: This update from Xvivo Perfusion AB could positively influence the company’s stock performance and investor sentiment by showcasing innovation in organ preservation technology. As the study progresses, successful outcomes could position Xvivo as a leader in the field, potentially impacting competitors and the broader industry.

The study is ongoing, with further details available on the ClinicalTrials portal.